Cancer clinical trials in the region Occitanie
385 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT07431827
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Localized
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Immunotherapy
Chemotherapy
1 recruiting site
Merck Sharp & Dohme LLC
Phase 3
Sarcoma and GIST
#NCT07218926
#2025-522229-37-00
Required histologic types
GIST
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KIT
PDGFRA
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
GlaxoSmithKline
Phase 3
Lung cancer
#NCT07185997
#2025-522151-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Bispecific T-cell engager antibodies
6 recruiting sites
ArriVent BioPharma, Inc
Phase 3
Endometrial cancer
#NCT07044336
#2024-518777-34-00
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
AstraZeneca
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04256317
Phase 3 monothérapie
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Secondary MDS
Chronic myelomonocytic leukemia (CMML)
Other MDS
Required previous treatments
Systemic Treatment-Naive
Required IPSS-R prognostic scores
High
Very high
Required IPSS-M prognostic scores
High
Very high
Required molecular CPSS scores
Intermediate-2
High
Excluded previous treatments
Chemotherapy
3 recruiting sites
Taiho Oncology
Phase 3
Lymphoma
#NCT06284122
#2023-505436-35-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required renal function statuses
30-50 ml/min
< 30 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Allogeneic stem cell transplant
Radiotherapy
37 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3
Kidney cancer
#NCT07227402
#2024-517136-21-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Immunotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Endometrial cancer
#NCT07022483
#2024-519444-33-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Carcinosarcoma
Required FIGO stages
Stage II
Stage III
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
POLE
4 recruiting sites
Daiichi Sankyo
Phase 3
Stomach and esophageal cancer
#NCT06901531
#2024-519773-19-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3
Multiple myeloma
#NCT05519085
#2023-509859-13-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
Celgene